Molecular alterations in pancreatic tumors

doi:10.3748/wjg.v27.i21.2710

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 21

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5291)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

421

WORD

240

HTML

3231

Tables (1-3)

244

Sum=4136

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

380

Download

775

Sum=1155

Jun 7, 2021 (publication date) through Jul 22, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jun 7, 2021; 27(21): 2710-2726
Published online Jun 7, 2021. doi: 10.3748/wjg.v27.i21.2710

Table 1 Main genetic alterations detectable in pancreatic ductal adenocarcinoma

Type of pancreatic lesion	Genetic alteration	Reported frequency (%)	Type of alterations	Role in clinical practice
PDAC	KRAS	70-90	Point mutations	Diagnostic/prognostic
	TP53	50-75	Point mutations/LOH	Prognostic
	CDKN2A/p16	90-98	Point mutations/LOH	Prognostic/genetic surveillance
	SMAD4	40-60	Point mutations/LOH	Prognostic
	BRCA1/2	5-10	Point mutations	Predictive/genetic surveillance
	NTRK1-3	< 1	Gene fusions	Predictive
	MSI	< 2	LOF	Predictive

The percentages quoted are estimated from the literature cited in the paper. Diagnostic role appears mainly in preoperative material. In bold those markers recommended for clinical practice by National Comprehensive Cancer Network 2019 guidelines. PDAC: Pancreatic ductal adenocarcinoma; LOH: Loss of heterozygosity.

Citation: Visani M, Acquaviva G, De Leo A, Sanza V, Merlo L, Maloberti T, Brandes AA, Franceschi E, Di Battista M, Masetti M, Jovine E, Fiorino S, Pession A, Tallini G, de Biase D. Molecular alterations in pancreatic tumors. World J Gastroenterol 2021; 27(21): 2710-2726
URL: https://www.wjgnet.com/1007-9327/full/v27/i21/2710.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i21.2710